United States
Q-Square Business Intelligence, Corp. (Q2BI) is a biometrical and clinical science contract research organization (CRO) for biopharmaceutical product/drug development and regulatory submissions. Established in 2009, Q2BI offers a wide array of expertise-based services including electronic data capture (EDC), clinical data management (CDM), medical coding (MC), Statistical Programming, Biostatistical science, safety monitoring, pharmacokinetics/pharmacodynamics (PK/PD) and consulting.
Operating in North America with a presence in greater New York, Boston, and San Francisco metropolitan areas, Q2BI has steadily grown and gained a reputable position in the biopharmaceutical world. The company focuses on providing high quality, flexible, and collaborative services to meet the diverse needs of pharmaceutical clients.
Q2BI's team boasts experience in over 1000 studies and has achieved 34 successful NDA/BLA submission approvals within various therapeutic areas. Additionally, the company is a pioneer in adopting CDISC, and the team supported the world's first FDA Project ORBIS.
As a biotechnology company headquartered in the United States, Q2BI prioritizes scientific understanding and impactful project delivery, emphasizing high-quality work and deliverables. The company trusts in its employees as the primary talent and asset, providing a unique, project sponsors-based business owner (BO) system and project-team settings for daily performance and demonstrations.
While details about the company's last investment and relevant investors are not provided, Q2BI's strong track record, expertise, and strategic focus within the biopharmaceutical industry make it an intriguing potential investment opportunity for venture capitalists seeking exposure to the biotechnology sector. Q2BI's established reputation, experienced team, and innovative approach position it as a promising candidate for future investment consideration.
